Safety Profiles of Newer Contraceptives presented at meeting of Society of Reproductive Investigation

RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017.  The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.

For more details see the presentation poster here.

 

Posted in

More RSI News

Quinolones and ALF risk

June 30, 2021
Risk Sciences International 1

Quinolones, a popular and powerful anti-biotic with broad coverage and reasonable safety, was concerned to be associated with acute liver failure (ALF). A study published…

Read News Item

US FDA FAERS and quinolones

June 22, 2021
RSI logo in white

Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…

Read News Item

Advancing Toxicity Testing webinar

May 25, 2021
Daniel Krewski at the CAAT Webinar

The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…

Read News Item

USC appoints Dr. Mattison distinguished professor

March 16, 2021
USC Arnold School of Public Health

Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…

Read News Item